Sheng Han

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 5

Top Topics

Cross Sectional

Chemotherapy Induced

Epidermal Growth Factor Receptor

Top Venues

Risk management and healthcare policy

International journal of clinical pharmacy

Advances in therapy

Evidence-based complementary and alternative medicine : eCAM

This page only lists publications with an associated author ORCID identifier.

Publications

Zhiyuan Wang, Ruilin Wang, Xiaoyu Li, Lin Bai, Pingan Fan, Yuanyuan Tang, Xin Li, Yangmu Huang, Xiaoyan Nie, Sheng Han, Luwen Shi, Jing Chen
Influencing Factors of Generic Prescribing Behavior of Physicians: A Structural Equation Model Based on the Theory of Planned Behavior. Risk management and healthcare policy 17 (2024)
Zhiyuan Wang, Ruilin Wang, Xiaoyu Li, Lin Bai, Pingan Fan, Yuanyuan Tang, Xin Li, Yangmu Huang, Xiaoyan Nie, Sheng Han, Luwen Shi, Jing Chen
Influencing Factors of Generic Prescribing Behavior of Physicians: A Structural Equation Model Based on the Theory of Planned Behavior. Risk management and healthcare policy 17 (2024)
Yingdan Cao, Hongbin Yi, Fenghao Shi, XiaoXia Wei, Sheng Han
Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States. International journal of clinical pharmacy (2024)
Haijing Guan, Chunping Wang, Zhigang Zhao, Sheng Han
Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China. Advances in therapy 39 (7) (2022)
Honghao Shi, Wanjie Guo, He Zhu, Meng Li, Carolina Oi Lam Ung, Hao Hu, Sheng Han
Cost-Effectiveness Analysis of Xiyanping Injection (Andrographolide Sulfonate) for Treatment of Adult Community Acquired Pneumonia: A Retrospective, Propensity Score-Matched Cohort Study. Evidence-based complementary and alternative medicine : eCAM 2019 (2019)